Improvement On Visual Tasking Activities And Workplace Productivity After 14 Days Of Acoltremon 0.003% Treatment: Integrated Analysis Of COMET Studies

Cory Lappin, OD, MS, FAAO

Cory Lappin, OD, MS, FAAO discusses Acoltremon 0.003%, a novel topical ocular neuromodulatory that increases natural tear production. In this video, Dr Lappin will review data that suggests Acoltremon 0.003% helps patients with moderate to severe DED perform daily activities and work more effectively. Dr. Lappin will review these clinical study results and their implications for the use of Acoltremon 0.003% as a treatment option for dry eye disease.